Emcure Pharmaceuticals Ltd successfully completes USFDA PAI of Oncology facility

The United States Food and Drug Administration ("US FDA") had conducted Pre-Approval Inspection ("PAI") of Emcure Pharmaceuticals Limited's manufacturing facility (Oncology) located at G.I.D.C., Taluka - Sanand, Ahmedabad - 382110, Gujarat, from June 30, 2025 to July 08, 2025. The inspection concluded without issuance of Form 483 (zero observations).

Shares of Emcure Pharmaceuticals Limited was last trading in BSE at Rs. 1256.20 as compared to the previous close of Rs. 1243.00. The total number of shares traded during the day was 5219 in over 435 trades.

The stock hit an intraday high of Rs. 1289.95 and intraday low of 1237.35. The net turnover during the day was Rs. 6510174.00.

Source : Equity Bulls

Keywords

EmcurePharmaceuticals INE168P01015 USFDA PAI OncologyManufacturingFacility ZeroObservations